Clinical Data

AstraZeneca, Ionis drug fails big heart disease study in major setback

BioPharma Dive

Eplontersen s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and boosted the outlook of rival drugs from Alnylam and BridgeBio Pharma.

Cardiovascular

Read full story

pharminent July 9, 2026 (Last updated: July 9, 2026)

BioPharma Dive

Eplontersen s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and boosted the outlook of rival drugs from Alnylam and BridgeBio Pharma.

Cardiovascular

Read full story

Related Stories

Roche’s KRAS drug tops its rivals in lung cancer trial

EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s

Evommune ends development of lead asset in chronic hives after mid-stage efficacy woes

You May Have Missed

AstraZeneca and Ionis Shares Fall After Wainua Misses Primary Endpoint in ATTR Cardiomyopathy Trial

Keenova eyes Xiaflex as first drug for plantar fibromatosis

AstraZeneca, Ionis drug fails big heart disease study in major setback

FDA freezes CRL trove as ‘radical transparency’ push hits speedbump